T. Rowe Price, a holding company that manages a group of 156 mutual funds, led a $110m Series C funding round in Generation Bio, a biotechnology company. The round had participation from investors Farallon, Wellington Management Company and existing investors Atlas Venture, Fidelity, Invus, Casdin, Deerfield and Foresite Capital. "Our vision is to develop re-dosable long-lasting gene therapies manufactured at a scale that leaves no patient or family behind. Since our founding, we have had the support of high-quality investors who share our excitement about our potential to lead a new generation of gene therapy as we advance our lead programs toward the clinic," Geoff McDonough, Generation Bio CEO.